Posaconazole trough concentrations are not influenced by inflammation: A prospective study

Patterson, 2016, Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis, 63, e1, 10.1093/cid/ciw326 Dekkers, 2016, Therapeutic drug monitoring of posaconazole: an update, Curr Fungal Infect Rep, 10, 51, 10.1007/s12281-016-0255-4 van der Elst, 2015, Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease, Ther Drug Monit, 37, 766, 10.1097/FTD.0000000000000235 Dolton, 2014, Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis, Antimicrob Agents Chemother, 58, 6879, 10.1128/AAC.03777-14 Bruggemann, 2009, Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents, Clin Infect Dis, 48, 1441, 10.1086/598327 Alffenaar, 2009, Omeprazole significantly reduces posaconazole serum trough level, Clin Infect Dis, 48, 839, 10.1086/597110 Dolton, 2012, Multicenter study of posaconazole therapeutic drug monitoring: exposure–response relationship and factors affecting concentration, Antimicrob Agents Chemother, 56, 5503, 10.1128/AAC.00802-12 Vaes, 2012, Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome, Antimicrob Agents Chemother, 56, 6298, 10.1128/AAC.01177-12 Tonini, 2012, Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease, Antimicrob Agents Chemother, 56, 5247, 10.1128/AAC.00815-12 Maertens, 2014, Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease, Antimicrob Agents Chemother, 58, 3610, 10.1128/AAC.02686-13 Kraft, 2014, Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects, Antimicrob Agents Chemother, 58, 4020, 10.1128/AAC.02448-13 van Wanrooy, 2014, Inflammation is associated with voriconazole trough concentrations, Antimicrob Agents Chemother, 58, 7098, 10.1128/AAC.03820-14 Encalada Ventura, 2015, Influence of inflammation on voriconazole metabolism, Antimicrob Agents Chemother, 59, 2942, 10.1128/AAC.04789-14 Veringa, 2017, Voriconazole metabolism is influenced by severe inflammation: a prospective study, J Antimicrob Chemother, 72, 261, 10.1093/jac/dkw349 Groll, 2005, Posaconazole: clinical pharmacology and potential for management of fungal infections, Expert Rev Anti Infect Ther, 3, 467, 10.1586/14787210.3.4.467 Wexler, 2004, Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study, Eur J Pharm Sci, 21, 645, 10.1016/j.ejps.2004.01.005 Ghosal, 2004, Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil), Drug Metab Dispos, 32, 267, 10.1124/dmd.32.2.267 Monshouwer, 1996, Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes, Toxicol Appl Pharmacol, 137, 237, 10.1006/taap.1996.0077 Sharp, 2017 Alffenaar, 2010, Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS, J Chromatogr B Analyt Technol Biomed Life Sci, 878, 39, 10.1016/j.jchromb.2009.11.017 Lempers, 2014, Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations, J Antimicrob Chemother, 69, 2988, 10.1093/jac/dku242 Krieter, 2004, Disposition of posaconazole following single-dose oral administration in healthy subjects, Antimicrob Agents Chemother, 48, 3543, 10.1128/AAC.48.9.3543-3551.2004 Congiu, 2002, UDP glucuronosyltransferase mRNA levels in human liver disease, Drug Metab Dispos, 30, 129, 10.1124/dmd.30.2.129 Del Giudice, 2018, Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters, Brain Behav Immun, 70, 61, 10.1016/j.bbi.2018.02.013 Illamola, 2015, Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines, Drug Discov Today, 20, 466, 10.1016/j.drudis.2014.11.010 Veringa, 2016, LC-MS/MS for therapeutic drug monitoring of anti-infective drugs, TrAC Trends Anal Chem, 84, 34, 10.1016/j.trac.2015.11.026 Jenkins, 2018, Simultaneous determination of voriconazole, posaconazole, itraconazole and hydroxy-itraconazole in human plasma using LCMS/MS, Clin Biochem, 53, 110, 10.1016/j.clinbiochem.2018.01.004 Rochat, 2010, Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing, Antimicrob Agents Chemother, 54, 5074, 10.1128/AAC.00022-10 Jeong, 2018, Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations, J Antimicrob Chemother, 73, 748, 10.1093/jac/dkx440